Tag Archives: Coronavirus

Antibody levels higher after Moderna shot; Lilly arthritis drug used with steroid cuts death risk

By Nancy Lapid

(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Antibody levels are higher after Moderna vaccine

The mRNA vaccine from Moderna Inc induces higher levels of antibodies against the coronavirus that causes COVID-19 than the similar vaccine from Pfizer Inc and partner BioNTech SE, Belgian researchers have found, although what this means for their efficacy is not clear. Soon after receiving their second shot, the 688 healthcare workers who got Moderna’s vaccine had antibody levels roughly twice as high as the 959 who received the Pfizer/BioNTech product, regardless of their ages, doctors at a Belgian medical center reported. This held true even after accounting for individual risk factors, and regardless of whether participants had previously been infected with the virus, the researchers reported on Monday in JAMA. Antibodies are just one component of the immune system’s defenses, however. The study cannot determine whether one vaccine is more effective at preventing infection or illness, or whether the antibodies induced stay longer in the blood before disappearing. Those questions, and others, require further investigation, the researchers said.

Arthritis drug adds to benefit of steroids in severe illness

Hospitalized COVID-19 patients died less often if they received Eli Lilly and Co’s rheumatoid arthritis drug baricitinib along with the other treatments their doctors had prescribed, according to a study published on Wednesday in The Lancet Respiratory Medicine. The randomized trial involved 1,525 seriously ill patients, all of whom needed extra oxygen to help with breathing. More than 90% were already receiving dexamethasone, a cheap generic steroid known to improve survival of critically ill COVID-19 patients. While baricitinib, sold under the brand name Olumiant, did not appear to keep patients from getting sicker, it did reduce their risk of dying. The 28-day and 60-day death rates were 5% lower among patients randomly assigned to receive baricitinib instead of a placebo. Baricitinib is already approved in the United States for use in hospitalized COVID-19 patients in combination with Gilead Science’s antiviral drug remdesivir. The two drugs together appear to have more benefit than remdesivir alone. In the new study, more than 80% of participants were not receiving remdesivir, suggesting that baricitinib also “has synergistic effects with other standard-of-care treatments,” including dexamethasone, researchers said.

Vaccine poses low risk for adults with high-risk allergies

Highly allergic adults can safely receive the COVID-19 vaccine from Pfizer/BioNTech, a new study suggests. Among the 8,102 patients with allergies in the Israeli study, 95% received the shots in routine settings because their risk of a severe allergic reaction to the vaccine was low, and no such reactions were reported. The remaining 429 patients, who were considered to be highly allergic, received the vaccines under careful supervision and were observed for two hours afterward. Nine had allergic reactions, including three who showed signs of potentially life-threatening anaphylaxis. All responded to treatment with epinephrine and no one had to be hospitalized, according to a report published on Tuesday in JAMA Network Open published with the study said lessons from this study of allergic reactions to the Pfizer vaccine are likely “generalizable to the Moderna” shot as well.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

More contagious Delta variant makes people sicker; oral drug shows promise in treating COVID-19 pneumonia

By Nancy Lapid

(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Delta variant makes people sicker

The Delta variant of the coronavirus is known to be more easily transmissible than earlier versions, and now a large UK study suggests it also makes people sicker. Researchers analyzed data on 43,338 patients infected with either the Alpha or the Delta variant. Overall, roughly three quarters were unvaccinated, and half were under age 31. After accounting for patients’ underlying risk factors, researchers found that unvaccinated patients were 132% more likely to be hospitalized if they were infected with Delta than with Alpha. Vaccinated patients may also be more likely to require hospitalization with a Delta infection, but data for those patients was less clear, according to a report published on Friday in The Lancet Infectious Diseases. The results “suggest that outbreaks of the Delta variant in unvaccinated populations might lead to a greater burden on healthcare services than the Alpha variant,” the researchers concluded.

Oral drug shows promise against COVID-19 pneumonia

Severely ill patients with COVID-19 pneumonia who received the experimental oral drug opaganib developed by RedHill Biopharma required less extra oxygen and were able to leave the hospital sooner than patients receiving a placebo in a small randomized trial, researchers reported on Sunday on medRxiv ahead of peer review. Within 14 days after enrolling in the study, 50.0% of patients taking opaganib no longer needed oxygen, compared to 22.2% of patients in the placebo group. In addition, 86.4% of opaganib-treated patients had been discharged, versus 55.6% in the placebo group. On Thursday, RedHill announced that opaganib strongly inhibits the Delta variant of the coronavirus in test tube experiments. The drug is believed to exert its antiviral effect by inhibiting sphingosine kinase-2 (SK2), a key enzyme in cells that may be recruited by the virus to support its replication, the company said. Based on the initial 42-patient trial conducted last year, RedHill Biopharma launched a much larger randomized trial in patients hospitalized with severe COVID-19 pneumonia. The last of the 475 patients in that late-stage study has now completed treatment and some of the data should be available soon, the company said last week.

Seizure in children may signal COVID-19

Seizures may be the only symptom of COVID-19 in some children, a new report cautions. Children tend to get sick from COVID-19 far less often than adults, and their symptoms are usually not severe, mainly consisting of fever and mild respiratory issues, although more have become ill with emergence of the Delta variant. Among 175 children who came to an Israeli emergency room and were diagnosed with COVID-19, 11 were brought to the hospital because of seizures, researchers reported on Saturday in the medical journal Seizure. Only seven had previously been diagnosed with a neurological disorder, and only six had fever. All 11 made full recoveries. While seizures have not been a frequently reported problem in adults with COVID-19, they “may be the main manifestation of acute COVID-19 in children,” even without fever and without a history of epilepsy, the study authors said. In some hospitals, they point out, only children with flu-like symptoms or close contact with a confirmed COVID-19 patient get tested for the coronavirus. Medical personnel should be aware that children with seizures should be tested, too, they said.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

Genes may add to ethnic COVID-19 disparities; sickest patients unwell a year later

By Nancy Lapid

(Reuters) – Here is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Genes may explain some ethnic differences in COVID-19 impact

The varying impacts of COVID-19 among ethnic groups might be partially due to genetic differences in the cell-surface protein the virus uses as a gateway, an international research team found. They analyzed genetic information from more than 85,000 volunteers, including 6,274 who were tested for the new coronavirus and 1,837 who tested positive. In the gene for ACE2 – the “receptor” protein through which the virus breaks into cells – they found rare variants that would alter the part of the protein to which the virus attaches itself. These variant genes “appear to vary in frequency between different ethnic groups,” said Jamal Nasir of the University of Northampton in the UK. Two were more common in Europeans than in East Asians, for example. Nasir and colleagues also found variants that appear to increase or decrease an individual’s ACE2 protein levels, which could affect vulnerability to infection, or severity. People who were not infected with the coronavirus were more likely to have a variant that decreases ACE2 levels, according to a report posted on Wednesday on medRxiv ahead of peer review. The next steps, Nasir said, are to confirm the findings by exposing human cells to the virus in lab experiments and to identify small molecules that can be used as drugs to block harmful genetic mutations’ effects.

Severe COVID-19 still affects patients a year later

Among 1,276 COVID-19 patients hospitalized in China early in the pandemic, 49% still had at least one symptom 12 months after first becoming ill, researchers reported on Friday in The Lancet. Most common were fatigue or muscle weakness. About a third still had shortness of breath or other lung problems, especially those who had been the most severely ill. In some patients, doctors saw a reduced flow of oxygen from the lungs to the bloodstream. Roughly one in four survivors reported depression. Among patients who had been employed before they were hospitalized, 88% had returned to work by 12 months – but overall, the survivors were not as healthy as people from the community who had not been infected with the coronavirus. The study only looked at patients from one hospital, and not many of them had been sick enough to require intensive care. Nevertheless, the fact that some patients still had symptoms “should be taken into account when planning delivery of healthcare services post-pandemic,” coauthor Bin Cao from the China-Japan Friendship Hospital said in a statement.

Pfizer vaccine safe in small study of very sick kids

In adolescents with serious neurological conditions, the side effects of the Pfizer/BioNTech vaccine are likely to be mild to moderate and clear up quickly, a small study suggests. The 27 children in the study, ages 12 to 15, had muscular dystrophy, cerebral palsy, or other neurological diseases, plus other conditions such as heart defects and immune deficiency – all of which put them at very high risk for severe COVID-19. They would not have been included in the main trials of the vaccine because they were too sick, the researchers said. Eleven children had averse events after the first or second dose, such as mild rash, fever, headache, gastrointestinal upset, difficulty sleeping, and low blood sugar. Most problems resolved within 72 hours, and the rest cleared up within a week, according to a report published on Thursday in Archives of Disease in Childhood. Although the study involved only a few children, “these data are especially important as they are representative of the children who are most likely to benefit from vaccination, and parents and clinicians may have concerns regarding an increased risk of unexpected events,” the authors said.

(Reporting by Nancy Lapid; Editing by Tiffany Wu)

Factbox – Latest on the worldwide spread of the coronavirus

(Reuters) – The World Health Organization’s (WHO) pandemic program plans to ship 100 million doses of Sinovac and Sinopharm COVID-19 shots by the end of next month, mostly to Africa and Asia, in its first delivery of Chinese vaccines, a WHO document showed.

EUROPE

* Britain’s Health Department said it has not made any decision on COVID-19 vaccines for 12 to 15-year-olds after the Telegraph reported the National Health Service planned vaccinations from the first week children return to school in September.

* The British public’s view of the government’s management of the coronavirus crisis has turned negative for the first time since February and they are worried about the risk of a new wave of infections, according to a survey.

* Hundreds of Greek frontline health workers protested against a plan to make COVID-19 vaccinations mandatory for the care sector as infection rates remained high.

* Students and teachers who have not been inoculated against COVID-19 or recovered from the disease will have to take weekly tests, as infections in the country rose to their highest since May.

ASIA-PACIFIC

* Vilified by Indian Prime Minister Narendra Modi’s party for its high COVID-19 cases, Kerala’s apparent poor record may actually hold crucial lessons for the country in containing the outbreak as authorities brace for a possible third wave of infections.

* Vietnam will deploy troops to industrial Binh Duong province, a major manufacturing hub in the Southeast Asian country, to help contain an expected 50,000 additional coronavirus infections there over the next two weeks, the government said.

* Thailand is in talks with European countries to purchase millions of doses of COVID-19 vaccines.

AMERICAS

* Illinois will require all eligible students and school employees to be vaccinated and re-instituted an indoor mask mandate under an order announced by Governor J.B. Pritzker.

* Public support for stronger measures to require COVID vaccinations is strong, according to a new Reuters/IPSOS poll, but for Detroit automakers the debate over vaccination policy is far from over.

MIDDLE EAST AND AFRICA

* A third wave of COVID-19 infections in Africa has stabilized and the continent’s slow vaccination drive has picked up pace, the WHO said.

* Qatar is offering COVID-19 vaccines to evacuees from Afghanistan who are temporarily staying in the Gulf Arab state, which has been facilitating global evacuation efforts since the Taliban seized Kabul.

MEDICAL DEVELOPMENTS

* Inovio Pharmaceuticals Inc said it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil’s regulatory agency.

* Pfizer Inc and BioNTech signed on Brazil’s Eurofarma Laboratorios as a manufacturer of their COVID-19 vaccine doses for Latin America.

* Pfizer said a booster dose of its two-shot COVID-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the company seeks U.S. regulatory approval for a third injection.

ECONOMIC IMPACT

* Global equity markets slipped while U.S. Treasury yields rose to two-week highs on Thursday after two hawkish Federal Reserve officials called for the U.S. central bank to start ending its bond-buying program ahead of a key speech by Fed Chair Jerome Powell.

(Compiled by Aditya Soni and Krishna Chandra Eluri; Editing by Subhranshu Sahu and Arun Koyyur)

China criticizes U.S. ‘scapegoating’ as COVID origin report to be released

BEIJING (Reuters) -China criticized on Wednesday the U.S. “politicization” of efforts to trace the origin of the coronavirus, demanding a U.S. military laboratory be investigated, shortly before the release of a U.S. intelligence community report on the virus.

The U.S. report is intended to resolve disputes among intelligence agencies considering different theories about how the coronavirus emerged, including a once-dismissed theory about a Chinese laboratory accident.

“Scapegoating China cannot whitewash the U.S.,” Fu Cong, director-general of the Ministry of Foreign Affairs’ arms control department, told a briefing.

A White House official said on Wednesday that President Joe Biden had been briefed on the classified report. “We look forward to having an unclassified summary of key judgments to share soon,” the official said.

U.S. officials say they did not expect the review to lead to firm conclusions after China stymied earlier international efforts to gather key information on the ground.

China has said a laboratory leak was highly unlikely, and it has ridiculed a theory that coronavirus escaped from a lab in Wuhan, the city where COVID-19 infections emerged in late 2019, setting off the pandemic.

China has instead suggested that the virus slipped out of a lab at the Army’s Fort Detrick base in Maryland in 2019.

“It is only fair that if the U.S. insists that this is a valid hypothesis, they should do their turn and invite the investigation into their labs,” said Fu.

On Tuesday, China’s envoy to the United Nations asked the head of the World Health Organization for an investigation into U.S. labs.

A joint WHO-Chinese team visited the Wuhan Institute of Virology but the United States said it had concerns about the access granted to the investigation.

When asked if China would stop talking about the Fort Detrick laboratory if the U.S. report concluded the virus did not leak from a Chinese lab, Fu said: “That is a hypothetical question, you need to ask the U.S.”

Fu said China was not engaged in a disinformation campaign.

(Reporting by Gabriel Crossley; additional reporting by Steve Holland in Washington; editing by Jonathan Oatis)

U.S. cannot say how many Afghan refugees it has received, situation ‘fluid’

By Andrea Shalal and Ted Hesson

WASHINGTON (Reuters) -A senior U.S. official on Tuesday could not say how many Afghans have been evacuated to the United States, adding that the situation remains “fluid” because of the swiftness of the operation.

Pressed to provide numbers, the official said the U.S. government was “moving as quickly as we can to get them out of harm’s way.”

“I don’t have exact numbers for you right now or a breakdown,” the official told reporters during a phone briefing. “Even if I did, it would shift as this process continues.”

President Joe Biden’s administration has scrambled to evacuate U.S. citizens and Afghan allies amid the chaos at Kabul airport ahead of an Aug. 31 deadline for U.S. forces to pull out of Afghanistan.

In the rush, the Biden administration has not said exactly how many Afghans have been allowed to enter the United States, a figure that could show the country’s commitment to resettling vulnerable Afghans but also potentially fuel concerns that Afghans could be entering the country without adequate security vetting.

Flights have arrived in the United States in recent days carrying U.S. citizens and Afghans.

After being tested for the coronavirus upon arrival, Americans can head to their homes, while others will go to a variety of U.S. military bases, where they will receive assistance in applying for work authorization, the senior official said on Tuesday.

The arriving Afghans will be connected with refugee resettlement organizations, said the official, who requested anonymity to discuss internal government operations.

Other Afghans evacuated by the United States have been sent to third-country transit points in Europe and Asia, the official said.

U.S. law enforcement and counterterrorism officials are carrying out “robust security processing” before those evacuees are allowed to enter the United States, including biometric and biographical checks, the official said.

(Reporting by Andrea Shalal and Ted Hesson in Washington; Editing by Ross Colvin and Grant McCool)

Children hospitalized with COVID-19 in U.S. hits record number

By Gabriella Borter

(Reuters) -The number of children hospitalized with COVID-19 in the United States hit a record high of just over 1,900 on Saturday, as hospitals across the South were stretched to capacity fighting outbreaks caused by the highly transmissible Delta variant.

The Delta variant, which is rapidly spreading among mostly the unvaccinated portion of the U.S. population, has caused hospitalizations to spike in recent weeks, driving up the number of confirmed and suspected pediatric COVID-19 hospitalizations to 1,902 on Saturday, according to data from the U.S. Department of Health and Human Services.

Reuters includes confirmed and suspected COVID-19 cases for hospitalization, case and death data.

Children currently make up about 2.4% of the nation’s COVID-19 hospitalizations. Kids under 12 are not eligible to receive the vaccine, leaving them more vulnerable to infection from the new, highly transmissible variant.

“This is not last year’s COVID. This one is worse and our children are the ones that are going to be affected by it the most,” Sally Goza, former president of the American Academy of Pediatrics, told CNN on Saturday.

The numbers of newly hospitalized COVID-19 patients aged 18-29, 30-39 and 40-49 also hit record highs this week, according to data from the U.S. Centers of Disease Control and Prevention (CDC).

The spike in new cases has ramped up tension between conservative state leaders and local districts over whether school children should be required to wear masks as they head back to the classroom this month.

School districts in Florida, Texas and Arizona have mandated that masks be worn in schools, defying orders from their Republican state governors that ban districts from imposing such rules. The administration of Florida Governor Ron DeSantis has threatened to withhold funding from districts that impose mask requirements, and Texas Governor Greg Abbott is appealing to the state Supreme Court to overturn Dallas County’s mask mandate, the Dallas Morning News reported on Friday.

A fifth of the nation’s COVID-19 hospitalizations are in Florida, where the number of hospitalized COVID-19 patients hit a record 16,100 on Saturday, according to a Reuters tally. More than 90% of the state’s intensive care beds are filled, according to data from the Department of Health and Human Services.

INCREASED HOSPITALIZATIONS

The nation’s largest teachers union, the National Education Association, came out in support of mandatory vaccination for its members this week. NEA President Becky Pringle said on Saturday that schools should employ every mitigation strategy, from vaccines to masks, to ensure that students can come back to their classrooms safely this school year.

“Our students under 12 can’t get vaccinated. It’s our responsibility to keep them safe. Keeping them safe means that everyone who can be vaccinated should be vaccinated,” Pringle told CNN.

The U.S. now has an average of about 129,000 new COVID-19 cases per day, a rate that has doubled in a little over two weeks, according to a Reuters tally. The number of hospitalized COVID-19 patients is at a six-month high, and an average of 600 people are dying each day of COVID-19, double the death rate seen in late July.

Arkansas, Florida, Louisiana, Mississippi, and Oregon have reported record numbers of COVID-19 hospitalizations this month, according to a Reuters tally, pushing healthcare systems to operate beyond their capacity.

“Our hospitals are working to maximize their available staff and beds, including the use of conference rooms and cafeterias,” Florida Hospital Association President Mary Mayhew said in a statement on Friday.

In Oregon, Governor Kate Brown said on Friday that she was sending 500 National Guard members to assist overwhelmed hospitals, with 1,500 members in total available to help.

In Jackson, Mississippi, federal medical workers are assisting understaffed local teams at a 20-bed triage center in the parking garage of the University of Mississippi Medical Center (UMMC) to accommodate the overflow of COVID-19 patients.

Fifteen children and 99 adults were hospitalized with COVID-19 at UMMC as of Saturday morning, the hospital said. More than 77% of those patients were unvaccinated.

(Reporting by Gabriella Borter and Lisa Shumaker; editing by Diane Craft and Aurora Ellis)

Factbox-Latest on the worldwide spread of the coronavirus

(Reuters) – The Tokyo Paralympics will take place generally without spectators, organizers said, as the government was set to prolong COVID-19 emergency measures in the capital and other regions that will run through the Games.

EUROPE

* The European Guarantee Fund, which is managed by the Investment Bank Group, secured European Union approval to provide guarantees on synthetic securitization tranches to help companies in 22 EU countries affected by the pandemic.

* Poland will send 650,000 doses of the AstraZeneca vaccine to Ukraine, the minister in charge of the Polish vaccination drive told state news agency PAP.

* North Macedonia has reimposed restrictions on access to cafes, restaurants and public events in a bid to subdue a fresh spike in infections and nudge citizens to get vaccinated, prompting public anger and protests.

* All 16- and 17-year-olds in England will be offered their first vaccine dose by Aug. 23, according to a target set by British Health Secretary Sajid Javid.

ASIA-PACIFIC

* Thailand, a regional manufacturer of AstraZeneca’s coronavirus shots, is seeking to borrow 150,000 doses of the same vaccine from the Himalayan kingdom of Bhutan, an official said, amid a Thai supply shortage.

* Indonesia extended its curbs though relaxed some measures in eight unspecified areas on the most populous islands of Java and Bali, as fewer infections have been reported in cities.

* Hong Kong’s government said it would upgrade 15 overseas places including the United States, Spain and France to “high risk” from “medium risk” by Aug. 20, meaning international arrivals from those countries will face lengthened quarantine due to a resurgence of the coronavirus.

* Taiwan has rejected an application for the emergency use of UBI Pharma’s vaccine candidate, the government said.

AMERICAS

* As the Delta variant of the virus sweeps through Mexico’s cities, more adults in their 30s and 40s are ending up in the hospital with polls showing vaccine hesitancy is rising in younger age groups.

MIDDLE EAST AND AFRICA

* Turkey is allowing people who were inoculated with Sinovac’s coronavirus vaccine to take an additional Pfizer dose as it looks to ease travel to countries that have not approved the Chinese shot, the health ministry said.

MEDICAL DEVELOPMENTS

* Europe’s drugs regulator said it was evaluating the use of Roche’s arthritis drug, Actemra, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment.

* The UK’s health regulator said coronavirus vaccines did not raise the risk of miscarriage, and that it had not found any link between the shots and changes to menstrual periods.

* GlaxoSmithKline and CureVac said a study on macaque monkeys showed their jointly-developed vaccine candidate to be “strongly improved” in protecting against the virus compared with CureVac’s first attempt.

ECONOMIC IMPACT

* A surprisingly sharp slowdown in Chinese economic activity and a rapid Taliban takeover in Afghanistan helped drive global shares lower Monday.

* The initial success of Israel’s COVID-19 vaccination rollout that enabled an opening of the economy bolstered growth in the second quarter, official figures showed.

* Thailand’s economy unexpectedly grew in the second quarter from the first helped by exports and government spending, but spiking cases continue to batter domestic activity and tourism, restraining its fragile recovery.

(Compiled by Veronica Snoj and Federico Maccioni; Edited by Shounak Dasgupta)

Factbox-Latest on the worldwide spread of the coronavirus

(Reuters) – Drugmakers Pfizer, BioNTech and Moderna are expected to make billions of dollars from COVID-19 booster shots in a market that could for years rival the $6 billion in annual sales for flu vaccines, analysts and healthcare investors say.

DEATHS AND INFECTIONS

EUROPE

* The German government has designated the Israel, Turkey and the United States as high-risk countries, triggering a minimum five-day quarantine requirement for those who are unvaccinated, the Funke media group reported.

* Russia reported a record 815 coronavirus-related deaths in the last 24 hours, but Moscow’s mayor said hospitalizations from the disease in the capital had halved over the last six weeks.

* Norway’s government will end some restrictions related to the pandemic, it said, but stopped short of announcing a full reopening of the economy.

ASIA-PACIFIC

* Indonesia’s capital reopened its retail malls this week to an exclusive crowd – shoppers vaccinated against coronavirus.

* China reported declining numbers of new locally transmitted cases for the third consecutive day. However, ports and shipping companies are diverting vessels from a container terminal in the country’s busiest marine transportation hub, which was forced to close after a case emerged.

* Japanese Prime Minister Yoshihide Suga urged people to refrain from travelling as COVID-19 cases spiked to records in Tokyo and nationwide, heaping pressure on the medical system.

* South Korea signed a deal to buy 30 million doses of Pfizer vaccine for 2022, and the government urged people to cut holiday travel amid a worsening fourth wave of infections and a slow inoculation campaign.

AMERICAS

* The U.S. Food and Drug Administration authorized a third dose of vaccines from Pfizer and Moderna for people with compromised immune systems.

* The United States has started shipping nearly 569,000 Pfizer vaccine doses to member countries of the Caribbean Community (CARICOM), the U.S. State Department said.

MIDDLE EAST AND AFRICA

* Morocco received a shipment of 600,000 doses of the Pfizer-BioNTech vaccine as it expands its inoculation campaign to younger people following a surge in cases, said Said Afif, a member of the health ministry’s scientific committee.

* South Africa’s health minister Joe Phaahla said authorities would not would recommend a relaxation of lockdown measures from its current Level 3, despite an overall downward trend in infections as the country grapples with a third wave.

* Israel lowered to 50 from 60 the minimum age of eligibility for a vaccine booster shot and will also offer it to health workers, hoping to stem a surge in Delta variant infections.

MEDICAL DEVELOPMENTS

* The World Health Organization said it was setting up a new group to trace the origins of the coronavirus, seeking to end what it called “political point scoring” that had hampered investigations.

* Indian vaccine maker Bharat Biotech’s nasal vaccine candidate has received regulatory approval for mid- to late-stage trials, the government’s ministry of science and technology said in a statement.

* A two-dose vaccine from China’s Sinopharm was 50.4% effective in preventing infections in health workers in Peru when it saw a surge in cases fueled by virus variants, and booster shots can be considered, a study found.

ECONOMIC IMPACT

* Global stock markets hit record highs on Friday, capping another bumper week as investors seized on a dip in U.S. inflation and more forecast-beating corporate earnings.

(Compiled by Veronica Snoj and Federico Maccioni; Editing by Shounak Dasgupta and Barbara Lewis)

WHO seeks to take political heat out of virus origins debate

By Emma Farge

GENEVA (Reuters) – The World Health Organization said on Friday it was setting up a new group to trace the origins of the coronavirus, seeking to end what it called “political point scoring” that had hampered investigations.

The inability of the WHO to say where and how the virus began spreading has fueled tensions among its members, particularly between China, where COVID-19 cases were first identified in Wuhan in late 2019, and the United States.

The WHO called for all governments to cooperate to accelerate studies into the origins of the COVID-19 pandemic and “to depoliticize the situation.”

It specified that a new advisory group called the International Scientific Advisory Group for Origins of Novel Pathogens would support “the rapid undertaking” of further studies.

“We should work all together. You, me, everyone wants to know the origin of worst pandemic in a century,” WHO spokesperson Fadela Chaib said at a U.N. briefing on Friday.

Washington on Friday welcomed the WHO plan, noting the “emphasis on scientific-based studies and data driven efforts to find the origins of this pandemic so that we can better detect, prevent and respond to future disease outbreaks.”

President Joe Biden in late May ordered aides to find answers on COVID-19 origins and report back in 90 days.

In its final report, written jointly with Chinese scientists, a WHO-led team that spent four weeks in and around the city of Wuhan in January and February said that the virus had probably been transmitted from bats to humans through another animal. It said that a leak from a laboratory was “extremely unlikely” as a cause.

However, in a documentary broadcast in his native Denmark on Thursday, the WHO mission leader Peter Ben Embarek said that the lab hypothesis merited further study. Ben Embarek could not be reached by Reuters for further comment on Friday.

A WHO official said that its statement on advancing the virus origins study bore no relation to those remarks, noting that the Ben Embarek interview was filmed months ago.

China said it has never rejected cooperation on tracing COVID-19 origins, state media quoted the country’s vice foreign minister as saying.

(Reporting by Emma Farge, Jacon Gronholt-Pedersen and Gabriel Crossley; Editing by Keith Weir and Jon Boyle)